JP2018519802A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519802A5 JP2018519802A5 JP2017560132A JP2017560132A JP2018519802A5 JP 2018519802 A5 JP2018519802 A5 JP 2018519802A5 JP 2017560132 A JP2017560132 A JP 2017560132A JP 2017560132 A JP2017560132 A JP 2017560132A JP 2018519802 A5 JP2018519802 A5 JP 2018519802A5
- Authority
- JP
- Japan
- Prior art keywords
- mutein
- nucleotide sequence
- nucleic acid
- encoded
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021127923A JP7217783B2 (ja) | 2015-05-18 | 2021-08-04 | グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167922.2 | 2015-05-18 | ||
| EP15167922 | 2015-05-18 | ||
| PCT/EP2016/061058 WO2016184875A1 (en) | 2015-05-18 | 2016-05-18 | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127923A Division JP7217783B2 (ja) | 2015-05-18 | 2021-08-04 | グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519802A JP2018519802A (ja) | 2018-07-26 |
| JP2018519802A5 true JP2018519802A5 (enExample) | 2019-06-20 |
| JP6942060B2 JP6942060B2 (ja) | 2021-09-29 |
Family
ID=53180583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560132A Expired - Fee Related JP6942060B2 (ja) | 2015-05-18 | 2016-05-18 | グリピカン−３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
| JP2021127923A Active JP7217783B2 (ja) | 2015-05-18 | 2021-08-04 | グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021127923A Active JP7217783B2 (ja) | 2015-05-18 | 2021-08-04 | グリピカン－３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10273275B2 (enExample) |
| EP (1) | EP3298029A1 (enExample) |
| JP (2) | JP6942060B2 (enExample) |
| KR (1) | KR20180008649A (enExample) |
| CN (2) | CN107787327B (enExample) |
| AU (1) | AU2016262838B2 (enExample) |
| BR (1) | BR112017020961A2 (enExample) |
| CA (1) | CA2982034A1 (enExample) |
| MX (1) | MX2017014730A (enExample) |
| RU (1) | RU2756318C2 (enExample) |
| SG (1) | SG11201707872WA (enExample) |
| WO (1) | WO2016184875A1 (enExample) |
| ZA (1) | ZA201706605B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201408073XA (en) | 2009-12-07 | 2015-01-29 | Pieris Ag | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| ES2823563T3 (es) | 2014-05-22 | 2021-05-07 | Pieris Pharmaceuticals Gmbh | Polipéptidos de unión específica novedosos y usos de los mismos |
| KR20170105609A (ko) | 2015-01-28 | 2017-09-19 | 피어이스 파마슈티컬즈 게엠베하 | 신생혈관형성에 특이적인 신규한 단백질 |
| EP4378962A3 (en) | 2015-05-04 | 2024-07-31 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
| DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| WO2016184875A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| MX390894B (es) * | 2015-05-18 | 2025-03-21 | Pieris Pharmaceuticals Gmbh | Polipéptido de fusión anti-cáncer. |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| SG11201803732PA (en) | 2015-11-30 | 2018-06-28 | Pieris Australia Pty Ltd | Novel anti-angiogenic fusion polypeptides |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| MX2021010039A (es) | 2019-02-26 | 2021-09-21 | Pieris Pharmaceuticals Gmbh | Novedosas proteinas de fusion especificas para cd137 y gpc3. |
| WO2020201038A1 (en) | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| CN116249709A (zh) | 2020-06-05 | 2023-06-09 | 皮里斯制药有限公司 | 靶向4-1bb的多聚体免疫调节剂 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE76311T1 (de) | 1986-08-19 | 1992-06-15 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| EP0759939B1 (en) | 1994-05-18 | 2005-07-20 | Nektar Therapeutics | Methods and compositions for the dry powder formulation of interferons |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (en) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Method for preparing dispersions of chromogenic components |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| EP1087778B1 (en) | 1998-06-08 | 2005-10-26 | F. Hoffmann-La Roche Ag | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| US7235520B2 (en) | 2000-09-21 | 2007-06-26 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
| WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| PT1923463E (pt) * | 2005-08-09 | 2011-11-24 | Oncotherapy Science Inc | Péptido antigénico de rejeição do cancro derivado de glipicano 3 (gpc3) para ser utilizado em doentes positivos para hla-a2 e composições farmacêuticas que contêm o antigénio |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| US8598317B2 (en) * | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
| WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| DE602007009995D1 (de) | 2006-08-01 | 2010-12-02 | Pieris Ag | Muteine von tearlipocalin und verfahren zu deren gewinnung |
| PL2178921T3 (pl) | 2007-07-17 | 2016-06-30 | Squibb & Sons Llc | Monoklonalne przeciwciała przeciwko glipikanowi-3 |
| WO2009052390A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| US8420051B2 (en) | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
| SG10201408073XA (en) | 2009-12-07 | 2015-01-29 | Pieris Ag | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| EP2576587B1 (en) | 2010-05-24 | 2018-03-21 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| WO2011154420A2 (en) | 2010-06-08 | 2011-12-15 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
| DK2606061T3 (da) | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | Bindingsproteiner til hepcidin |
| DK2640740T3 (en) * | 2010-11-15 | 2017-06-26 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) |
| US20130225505A1 (en) | 2011-11-23 | 2013-08-29 | Allergan, Inc. | Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| EP3441400B1 (en) * | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| KR20170105609A (ko) | 2015-01-28 | 2017-09-19 | 피어이스 파마슈티컬즈 게엠베하 | 신생혈관형성에 특이적인 신규한 단백질 |
| KR20170116158A (ko) | 2015-02-18 | 2017-10-18 | 사노피 | 피오베르딘 및 피오켈린에 특이적인 신규한 단백질 |
| DK3292137T3 (da) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | Proteiner specifikke for cd137 |
| WO2016184875A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
-
2016
- 2016-05-18 WO PCT/EP2016/061058 patent/WO2016184875A1/en not_active Ceased
- 2016-05-18 US US15/575,271 patent/US10273275B2/en active Active
- 2016-05-18 MX MX2017014730A patent/MX2017014730A/es unknown
- 2016-05-18 EP EP16729194.7A patent/EP3298029A1/en not_active Withdrawn
- 2016-05-18 JP JP2017560132A patent/JP6942060B2/ja not_active Expired - Fee Related
- 2016-05-18 SG SG11201707872WA patent/SG11201707872WA/en unknown
- 2016-05-18 RU RU2017135605A patent/RU2756318C2/ru active
- 2016-05-18 CN CN201680028942.8A patent/CN107787327B/zh not_active Expired - Fee Related
- 2016-05-18 KR KR1020177036061A patent/KR20180008649A/ko not_active Ceased
- 2016-05-18 CN CN202210050736.4A patent/CN114456252A/zh active Pending
- 2016-05-18 BR BR112017020961-6A patent/BR112017020961A2/pt not_active Application Discontinuation
- 2016-05-18 AU AU2016262838A patent/AU2016262838B2/en not_active Ceased
- 2016-05-18 CA CA2982034A patent/CA2982034A1/en active Pending
-
2017
- 2017-10-02 ZA ZA2017/06605A patent/ZA201706605B/en unknown
-
2019
- 2019-04-19 US US16/389,115 patent/US10787491B2/en not_active Expired - Fee Related
-
2021
- 2021-08-04 JP JP2021127923A patent/JP7217783B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519802A5 (enExample) | ||
| JP2018532372A5 (enExample) | ||
| JP2018515084A5 (enExample) | ||
| JP2014502149A5 (enExample) | ||
| RU2016149596A (ru) | Новые полипептиды со специфическим связыванием и пути их применения | |
| JP2017518748A5 (enExample) | ||
| JP2021006024A5 (enExample) | ||
| JP2020505948A5 (enExample) | ||
| JP2019506140A5 (enExample) | ||
| US10233238B2 (en) | TNF alpha antibody or fragment thereof and methods of use | |
| JP2013512683A5 (enExample) | ||
| RU2015137158A (ru) | МУТЕИНЫ ЛИПОКАЛИНА 2 ЧЕЛОВЕКА (Lcn2,hNGAL) С АФФИННОСТЬЮ ДЛЯ ОПРЕДЕЛЕННОЙ МИШЕНИ | |
| JP2018526989A5 (enExample) | ||
| RU2019122482A (ru) | Мутеины липокалина с аффинностью связывания в отношении lag-3 | |
| RU2017128105A (ru) | Новые белки, специфические в отношении ангиогенеза | |
| JP2018509887A5 (enExample) | ||
| CN114539411B (zh) | 一种ror1抗体或其抗原结合片段 | |
| JP2018519803A5 (enExample) | ||
| AU2014314222B2 (en) | Stable polypeptides binding to human complement C5 | |
| JP2002542157A5 (enExample) | ||
| KR20150058454A (ko) | 알부민 결합 폴리펩타이드 | |
| JP2016519051A5 (enExample) | ||
| CN110167959A (zh) | 用于监测对免疫检查点抑制剂pd1和pd-l1的抗体治疗的免疫测定和工程化蛋白 | |
| KR20160138133A (ko) | 안정화된 피브로넥틴 기반 스캐폴드 분자 | |
| ZA200601900B (en) | Therapeutic uses of chemokine variants |